Summary
Global Markets Direct’s, ‘Grunenthal GmbH - Product Pipeline Review - 2016’, provides an overview of the Grunenthal GmbH’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Grunenthal GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Grunenthal GmbH
- The report provides overview of Grunenthal GmbH including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Grunenthal GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Grunenthal GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Grunenthal GmbH’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Grunenthal GmbH
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Grunenthal GmbH’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Grunenthal GmbH Snapshot 5
Grunenthal GmbH Overview 5
Key Information 5
Key Facts 5
Grunenthal GmbH - Research and Development Overview 6
Key Therapeutic Areas 6
Grunenthal GmbH - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Grunenthal GmbH - Pipeline Products Glance 13
Grunenthal GmbH - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Grunenthal GmbH - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Grunenthal GmbH - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Grunenthal GmbH - Unknown Stage Pipeline Products 18
Unknown Products/Combination Treatment Modalities 18
Grunenthal GmbH - Drug Profiles 19
cebranopadol 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
tapentadol hydrochloride 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecule 1 for Pain 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule 2 for Pain 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
GRTTA-2210 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
RO-656570 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule 3 for Pain 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Activate KCNQ and TSPO for Pain 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Grunenthal GmbH - Pipeline Analysis 32
Grunenthal GmbH - Pipeline Products by Target 32
Grunenthal GmbH - Pipeline Products by Route of Administration 34
Grunenthal GmbH - Pipeline Products by Molecule Type 35
Grunenthal GmbH - Pipeline Products by Mechanism of Action 36
Grunenthal GmbH - Recent Pipeline Updates 38
Grunenthal GmbH - Dormant Projects 40
Grunenthal GmbH - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
axomadol 41
lexanopadol 41
Grunenthal GmbH - Company Statement 42
Grunenthal GmbH - Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47
List of Tables
Grunenthal GmbH, Key Information 5
Grunenthal GmbH, Key Facts 5
Grunenthal GmbH - Pipeline by Indication, 2016 7
Grunenthal GmbH - Pipeline by Stage of Development, 2016 9
Grunenthal GmbH - Monotherapy Products in Pipeline, 2016 10
Grunenthal GmbH - Partnered Products in Pipeline, 2016 11
Grunenthal GmbH - Partnered Products/ Combination Treatment Modalities, 2016 12
Grunenthal GmbH - Phase III, 2016 13
Grunenthal GmbH - Phase II, 2016 14
Grunenthal GmbH - Phase I, 2016 15
Grunenthal GmbH - Preclinical, 2016 16
Grunenthal GmbH - Discovery, 2016 17
Grunenthal GmbH - Unknown, 2016 18
Grunenthal GmbH - Pipeline by Target, 2016 33
Grunenthal GmbH - Pipeline by Route of Administration, 2016 34
Grunenthal GmbH - Pipeline by Molecule Type, 2016 35
Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2016 37
Grunenthal GmbH - Recent Pipeline Updates, 2016 38
Grunenthal GmbH - Dormant Developmental Projects,2016 40
Grunenthal GmbH - Discontinued Pipeline Products, 2016 41
Grunenthal GmbH, Other Locations 43
Grunenthal GmbH, Subsidiaries 44
List of Figures
Grunenthal GmbH - Pipeline by Top 10 Indication, 2016 7
Grunenthal GmbH - Pipeline by Stage of Development, 2016 9
Grunenthal GmbH - Monotherapy Products in Pipeline, 2016 10
Grunenthal GmbH - Partnered Products in Pipeline, 2016 11
Grunenthal GmbH - Pipeline by Target, 2016 32
Grunenthal GmbH - Pipeline by Route of Administration, 2016 34
Grunenthal GmbH - Pipeline by Molecule Type, 2016 35
Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2016 36
